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Abstract
Matrix metalloproteinase-13 is a uniquely important collagenase that promotes the irreversible destruction 
of cartilage collagen in osteoarthritis (OA). Collagenase activation is a key control point for cartilage 
breakdown to occur, yet our understanding of the proteinases involved in this process is limited. Neutrophil 
elastase is a well-described proteoglycan-degrading enzyme which is historically associated with 
inflammatory arthritis, but more recent evidence suggests a potential role in OA. In this study, we 
investigated the effect of neutrophil elastase on OA cartilage collagen destruction and collagenase 
activation. Neutrophil elastase induced significant collagen destruction from human OA cartilage ex vivo, 
in an MMP-dependent manner. In vitro, neutrophil elastase directly and robustly activated proMMP-13, 
and N-terminal sequencing identified cleavage close to the cysteine switch at 72MKKPR, ultimately 
resulting in the fully active form with the neo-N terminus of 85YNVFP. Mole-per-mole, activation was 
more potent than by MMP-3, a classical collagenase activator. Elastase was detectable in human OA 
synovial fluid, and OA synovia which displayed histologically graded evidence of synovitis. Bioinformatic 
analyses demonstrated that, compared with other tissues, control cartilage exhibited remarkably high 
transcript levels of the major elastase inhibitor, alpha-1 antitrypsin (AAT; gene name SERPINA1), but these 
were reduced in OA. AAT was located predominantly in superficial cartilage zones, and staining enhanced 
in regions of cartilage damage. Finally, active MMP-13 specifically inactivated AAT by removal of the 
serine proteinase cleavage/inhibition site. Taken together, this study identifies elastase as a novel activator 
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Osteoarthritis (OA) is a highly prevalent, degenerative joint disease which causes significant pain and 
disability. The progressive and irreversible destruction of the articular cartilage is the central characteristic 
of the disease. Cartilage is composed of two major components, the highly charged proteoglycan aggregate 
aggrecan and type II collagen, which is the major structural component of cartilage exhibiting a tightly 
interlocking triple helix, making it particularly resistant to proteolysis. Due to slow rates of synthesis, the 
loss of collagen is an essentially irreversible process [1], making it a critical therapeutic intervention point 
to prevent further cartilage breakdown. The crucial effector proteinases in this destruction are matrix 
metalloproteinases (MMPs) - specifically a sub-group known as the classical collagenases (MMP-1, -8 and 
-13). A wealth of evidence implicates MMP-13 (collagenase-3) with OA development and progression [2]. 
Indeed, this collagenase has the highest efficiency for cleavage of type II collagen [3], and MMP-13-
deficient mice are protected from cartilage destruction in experimental OA [4]. However, MMP inhibition 
has failed clinically, with patients presenting with a range of off-target effects including arthralgia - 
referred to as ‘musculoskeletal syndrome’[5]. This failure is attributed to a lack of inhibitor selectivity, 
which is a major hurdle, due to a common active-site architecture amongst different MMPs, many of which 
are considered ‘anti-targets’ – proteins to be avoided for therapeutic inhibition [6]. Although new 
generations of MMP-13 inhibitors exhibit markedly improved selectivity [7], none have been clinically 
successful thus far. 
An essential control point in the degradation of cartilage collagen is the activation of proMMPs [8-11] and 
may represent a novel method to reduce or block cartilage breakdown. Although some MMPs, such as 
MMP-3 are capable of collagenase activation [3], serine proteinases have long been postulated as putative 
in vivo activators [12, 13] and are more amenable for drug development [14, 15]. These enzymes are often 
assumed to be cartilage-derived, but the synovium can also be a source of proteinases [16]. Despite 
historically being referred to as a ‘non-inflammatory’ arthritis, recent evidence suggests a significant 
inflammatory component to OA progression, at least within certain sub-groups of patients [17]. Several 
studies have recently reported that activated macrophages and neutrophils within the synovium contribute 
to the severity of knee OA, and that the serine proteinase neutrophil elastase may act as a functional 
biomarker for OA progression in this joint [18-22]. 
Neutrophil elastase is located primarily in azurophilic granules of polymorphonuclear leukocytes and 
released upon cell degranulation [23]. The proteinase cleaves preferentially after small hydrophobic 
residues, and has a range of substrates, and well-established roles such as pathogen digestion and cellular 
extravasation [24, 25]. The major inhibitor of elastase is alpha-1 antitrypsin (AAT), a member of the serine 
proteinase inhibitor (serpin) superfamily, encoded by the SERPINA1 gene. This is perhaps most evident in 
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uncontrolled neutrophil elastase activity in the lung [26]. This inflammatory proteinase has been proposed 
as a drug target in numerous disorders, and a commercially available inhibitor, Sivelestat has been 
approved for acute respiratory distress syndrome (ARDS), but only in specific jurisdictions [27, 28].
The potent, direct cleavage of cartilage proteoglycan by neutrophil elastase has been demonstrated 
previously, both in vitro and in vivo [29, 30]. Indeed, a role for neutrophil elastase in cartilage destruction 
in rheumatoid arthritis (RA) has long been postulated [31-33]. More recently, it has been demonstrated that 
neutrophil elastase inhibition reduces chronic pain in mice that have undergone monoiodoacetate injection 
to induce OA [34], and reduces structural changes in rats following induction of post-traumatic knee OA 
[35]. Considering these observations, we investigated the effect of neutrophil elastase in OA cartilage 
collagenolysis, and in particular explored the biochemical interplay with the major collagenase in OA, 
MMP-13.
Results
Neutrophil elastase induces collagen release from human OA cartilage in explant culture in an MMP-
dependent manner. 
To investigate the effect of neutrophil elastase on human OA knee cartilage, explant culture experiments 
were performed. Neutrophil elastase potently and reproducibly induced the destruction of cartilage 
proteoglycan and collagen. To investigate whether this destruction was direct or indirect, a broad-spectrum 
MMP inhibitor, GM6001 was utilised. Elastase induced collagen release was markedly reduced in the 
presence of this inhibitor (Fig.1A) which correlated with reduced MMP activity in the conditioned medium 
(Fig.1B), whereas proteoglycan release was unaffected (Fig.1C). GM6001 does not affect the activity of 
neutrophil elastase directly (Fig.1D) and its vehicle control (DMSO) had no effect on cartilage matrix 
destruction. When the serpin neutrophil elastase inhibitor AAT was also included ECM degradation was 
abrogated, demonstrating the requirement for elastolytic activity to induce cartilage degradation, both 
directly (proteoglycan release) and indirectly (collagen release).
Neutrophil elastase activates proMMP-13.
As collagen release was MMP-dependent we hypothesised that neutrophil elastase could activate proMMPs 
which promote collagenolysis. To determine whether elastase can directly activate procollagenases, in vitro 
incubation experiments were performed using recombinant enzymes followed by an MMP-specific 
fluorogenic peptide substrate. In this system, neutrophil elastase induced very modest activation of 
proMMP-1 (Fig.2A) and no activation of proMMP-8 (Fig.2B). However when incubated with proMMP-13 
it induced robust activation of the collagenase, to a similar level as the chemical activator APMA (Fig.2C). 
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amount of active MMP-3, while matriptase and hepsin failed to significantly activate proMMP-13 
(Fig.2D), in line with previous observations [36, 37]. 
Neutrophil elastase fully activates MMP-13, generating the 85YNVFP neo-N-terminus.
To demonstrate that proMMP-13 was processed into its active form, an activation time-course was 
performed. Neutrophil elastase rapidly converted proMMP-13 into a 45 kDa species which corresponds to 
the fully active form as demonstrated by treatment with APMA (Fig.3A+B). APMA also generated an 
additional band of a lower molecular weight, likely due to continued autoproteolysis of MMP-13. A dose-
response experiment was conducted to assess the kinetics of processing in more detail. We observed 
optimum activation at a 1:5 enzyme to substrate ratio, but processing and increased MMP activity were 
observed at as low as 1:100. A 1:1 ratio resulted in slightly lower MMP activity, consistent with a reduced 
level of active MMP-13, suggesting a degree of non-specific proteolysis at this higher concentration 
(Fig.3C+D). The inclusion of the metalloproteinase inhibitor GM6001, led to the formation of an 
intermediate species (Fig.3E). N-terminal sequencing was performed to identify cleavage sites. Neutrophil 
elastase alone generated the 85YNVFP neo-N-terminus, whilst the predominant form in the presence of 
GM6001 was 72MKKPR (Fig.3F). To demonstrate the activation of proMMP-13 following neutrophil 
degranulation, blood-purified neutrophils were primed with GM-CSF then subsequently stimulated with a 
degranulation cocktail of cytochalasin B and the bacterial peptide stimulant fMLP. Neutrophil elastase 
(Fig.4A) and proteolytic activity against an elastase-specific quenched fluorescent peptide MeOSuc-
AAPV-AMC (Fig.4B) were detectable in supernatants from degranulated neutrophils. When degranulation 
supernatants were incubated with proMMP-13 they induced rapid activation, as determined by an MMP-
specific fluorogenic assay and a shift to the active 45 kDa form, an effect that was abrogated by the 
inclusion of AAT (Fig. 4C +D).
Neutrophil elastase is detectable in inflamed OA synovium and OA synovial fluid.
Neutrophil elastase is poorly expressed in cartilage [38, 39], so to determine whether neutrophil elastase 
could be detected in the OA joint, an immunohistochemical examination of human OA synovial tissues was 
performed. In total, 17 human OA synovia were scored histologically using a previously described 
synovitis scoring system [37, 40]. Neutrophil elastase was virtually undetectable in tissues with no 
synovitis but was detectable in invading leukocytes and in blood vessels of samples categorised as having 
‘slight’ or ‘moderate’ synovitis. MMP-13 however was detectable at all levels of synovitis, although 
staining was observed predominantly in fibroblasts in no/low synovitis samples and often in invading 
leukocytes in higher grades (Fig.5A). To determine the presence of neutrophil elastase and MMP-13 in OA 
synovial fluid, ELISAs were performed on fluid which was taken at the time of joint arthroplasty. 
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between patients (mean (±SD): 6374 (± 5745) pg/ml, n=8; Fig.5B). MMP-13 was detectable in all except 3 
OA synovial fluid samples (mean (±SD): 584 (± 760) pg/ml, n=8; Fig.5C). In this small sample size, 
neutrophil elastase did not correlate with MMP-13 (Fig.5D) and neither proteinases significantly correlated 
with erthyrocyte sedimentation rate (ESR), a marker of systemic inflammation (Fig.5E+F).
The neutrophil elastase inhibitor, AAT is abundant in cartilage and is observed predominantly in the 
superficial layer. 
Serine proteinase activity is regulated by endogenous inhibitors, the largest family of which are the serpins. 
To determine relative serpin expression in human cartilage we interrogated our previously published 
RNAseq data (GSE111358; [39]). In non-OA control human hip cartilage, several serpins were highly 
abundant, with 10 serpins having transcripts per million (TPM) counts of 10 or more. Of these, the 
SERPINA1 gene, encoding AAT, the major neutrophil elastase inhibitor, was particularly abundant with a 
TPM count exceeding 7000. Indeed, SERPINA1 was the 9th most abundant transcript within this dataset 
(Fig.6A). Using the human protein atlas, cross-tissue expression levels were determined. Interestingly, 
SERPINA1 expression was markedly enriched in cartilage, second only to expression within the liver 
(Fig.6B). When comparing macroscopically intact hip OA cartilage to control non-OA (NOF fracture) hip 
cartilage, levels of SERPINA1 transcript were markedly downregulated (padj=0.004; Fig.6C). To determine 
specific localisation of the AAT protein within human cartilage, immunohistochemistry revealed that the 
staining was particularly strong in the upper regions of the cartilage matrix, consistent with expression 
predominantly in the superficial cartilage layer. In undamaged cartilage the staining was principally 
localised to the chondrocyte, but interestingly, staining intensity was markedly increased in areas of 
damaged ECM, with intense AAT staining in the most damaged areas of OA cartilage (Fig.6D).
MMP-13 inactivates AAT at two sites, removing the reactive-centre loop
MMPs have previously been demonstrated to inactivate AAT by removing the reactive-centre loop required 
for irreversible inhibition of target proteinases [41]. Here, we demonstrate that in vitro incubation of AAT 
with active MMP-13 results in the generation of a single protein band - even after a 16-hour incubation - 
with a lower molecular size than that of native AAT (Fig.7A), and AAT is no longer able to inhibit 
neutrophil elastase (Fig.7B). A time-course experiment was performed, and products separated using tris-
glycine (protein) or tris-tricine (peptide) SDS-PAGE (Fig.7C). N-terminal sequencing revealed that MMP-
13 cleaved AAT at two sites, 377LEAIP and 382MSIPP (Fig.7D), upstream of the canonical neutrophil 
elastase cleavage site. Thus, active MMP-13 induces a specific inactivation of AAT, removing the 
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In this study we demonstrate that neutrophil elastase is a potent activator of the major OA collagenase, 
MMP-13. Historically described as non-inflammatory arthritis, it is becoming clear that OA is a disease of 
the whole joint, and that inflammation contributes to the disease processes, at least in a significant 
subgroup of patients [16]. The importance of the synovium in OA is becoming increasingly apparent, 
making factors often thought of having a role only in inflammatory arthritis progression - including 
proteinases - of renewed interest for study in OA. 
Serine proteinases have been shown to be important in the proteolytic cascades leading to cartilage 
destruction previously [8, 9, 12, 36, 37, 42], although identifying the specific proteinases involved is 
challenging. Indeed, the conversion of proMMP-13 into its active form is an essential, yet often 
overlooked, control point for the breakdown of cartilage collagen in OA. To our knowledge, the only 
described direct serine proteinase activators of MMP-13, are trypsin [3] and plasmin [43], with the former 
lacking physiological relevance to the joint, while the latter has a complex and debated role in arthritis [44]. 
This is the first study to describe the direct and full activation of proMMP-13 by neutrophil elastase. This 
serine proteinase has often been linked to the pathophysiology of RA and has been previously shown to be 
present in patient synovial fluid [45-47]. Indeed, systemic administration of human plasma AAT, reduced 
arthritis scores and joint destruction in murine collagen-induced arthritis [48], and mice deficient for 
neutrophil elastase and the related proteinase cathepsin-G, are also protected in this model [32]. As a 
relatively broad-spectrum serine proteinase the role of neutrophil elastase has been considered one of 
matrix destruction, and it has been shown to directly degrade proteoglycans [30, 49]. The data in our study 
are consistent with this, as neutrophil elastase-induced proteoglycan release in human OA cartilage was 
insensitive to metalloproteinase inhibition, and therefore direct. Elastase has previously been shown to 
directly cleave type III collagen in vitro, but was unable to cleave type I collagen [50]. The hydroxyproline 
assay is a sensitive and specific way to measure collagen breakdown from cartilage in explant culture [37, 
42, 51]. Cartilage is composed overwhelmingly of type II collagen (>90%; [52]), but does include other 
minor collagens such as type IX and type XI, which elastase has been shown to degrade directly, at least in 
vitro [53]. In our study we observed up to 15% collagen release from human OA cartilage, which was 
mediated by metalloproteinase activity, not the direct activity of elastase. The unique structure of triple-
helical collagen makes it susceptible to significant proteolysis from only a very restricted number of 
collagenases, likely due to important interactions of exosites required for unfolding of the triple-helix [54, 
55]. Although proteoglycan breakdown by neutrophil elastase is well established, the finding that this 
proteinase can induce MMP-dependent collagen degradation is important, as this is an irreversible step in 
the process of joint destruction [1]. Indeed, explant data in this study indicate that a pool of latent 
collagenases exist within diseased OA cartilage, something which has been observed in other studies 
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activity and collagen neo-epitopes generated by a collagenase has been observed in the synovial fluids of 
patients with non-infectious knee joint synovitis previously [57]. Although neutrophil elastase has been 
shown to be an activator of other MMPs [13, 58], here we demonstrate that it is a direct activator of the 
collagenase most commonly associated with OA, MMP-13. [12]. Under the described experimental 
conditions, neutrophil elastase was unable to significantly activate proMMP-8 while providing only modest 
activation of proMMP-1, further supporting a role for MMP-13 in neutrophil elastase-induced collagen 
destruction. Degranulation experiments further demonstrated a rapid activation of proMMP-13, which 
could be blocked in the presence of AAT.  Neutrophil degranulation products have previously been shown 
to induce cartilage breakdown in porcine cartilage explants, with neutrophil elastase implicated in the 
process [59]. Neutrophil elastase was detectable in all synovial fluid samples tested. While these levels are 
likely to be significantly lower than concentrations observed in RA [45], it is important to recognise that 
OA is disease of slow progression. Furthermore, the timing of sample collection will likely be of critical 
importance. For example, levels of neutrophil elastase have been shown to be high immediately after sports 
injury, but then gradually reduce over a 90 day period [60]. Periodic, localised inflammation could 
contribute to temporary release of neutrophil elastase into the OA joint, which could contribute to collagen 
degradation through MMP-13 activation. 
The serpins are a superfamily of structurally similar proteins, the majority of which inhibit serine 
proteinases, and we have recently described their emerging role in cartilage [61]. In this study, we have 
identified remarkably high transcript expression levels of SERPINA1 gene in human cartilage. Indeed, 
others have demonstrated high levels of the AAT protein within synovial fluid previously [62, 63]. This 
serpin is a serum protein with levels in the blood of approximately 0.9-2 mg/ml [64], the vast majority of 
which is produced in the liver [65]. Here, we show that levels of SERPINA1 transcript in human cartilage 
are second only to those in the liver. An interesting study which used microdissection and iTRAQ 
proteomics to investigate the protein composition of human cartilage layers found AAT to be mainly 
located in the upper levels of cartilage [66]. Indeed, this is something we also observed in our current 
study. It is important to recognise that AAT has multiple proteinase targets, although neutrophil elastase is 
by far the most kinetically favourable (Ka = 6.5 x107 M-1s-1; [24, 67]). It is plausible that AAT may act as a 
‘first line of defence’ against damaging immune cell-derived serine proteinases following degranulation. 
We also observed that AAT localises to damaged cartilage regions which requires further investigation. 
Possible reasons could include a localised damage response or that greater levels of AAT from the synovial 
fluid are able to penetrate the cartilage following significant degradation of the proteoglycan matrix (as 
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High SERPINA1 expression in cartilage raises important questions about the physiological relevance of 
neutrophil elastase deposition from an inflamed synovium. Indeed, using the total protein ELISAs 
undertaken in this study, it is not possible to determine the level of active neutrophil elastase or the level of 
functional AAT protein. However, it has been previously demonstrated that cartilage-bound neutrophil 
elastase is protected from the activity of proteinase inhibitors [68]. Moreover, serpins can be inactivated by 
other proteinases, as well as by oxidation, both of which have been demonstrated in the RA joint previously 
[69-71]. These mechanisms suggest total serpin levels may not be representative of the effective inhibitor 
concentrations within the joint. In this study, we describe the inactivation of AAT by MMP-13. Whilst this 
finding is novel, it is likely that in vivo, several MMPs may contribute to the inactivation of this inhibitor. 
Indeed, this serpin has been shown to be inactivated by MMP-1, MMP-2 and MMP-3 previously and the 
inactivated form has been observed in the synovial fluid of arthritis patients [70, 71]. Here we have 
identified cleavage sites generated by MMP-13 which correspond to regions N-terminal of the canonical 
cleavage site of neutrophil elastase (M382 is the neo-N-terminus generated following this 
cleavage/inhibition). Both sites have been identified as cleavage sites for other MMPs [71]. Future studies 
could involve the generation of neo-epitope antibodies which specifically recognise MMP-cleaved AAT. 
Such antibodies could be used to determine the level of AAT inactivation within the synovial joint of OA 
patients and the likely proteolytic source. Alternatively, the relative levels of different AAT 
(cleaved/uncleaved or complexed) could be determined by mass spectrometry approaches. The disarming 
of cognate inhibitor(s) will make joints more susceptible to the damaging effects of serine proteinases 
which present during periods of localised inflammation. A working hypothesis regarding the interplay 
between MMP-mediated AAT inactivation and proMMP-13 activation by neutrophil elastase is outlined in 
Fig.7E. A corollary of this hypothesis is the crucial role of functional AAT in mediating joint protection. 
To our knowledge, studies investigating the susceptibility of cartilage for degradation in OA (or indeed 
other arthritic diseases), in patients with alpha-1 antitrypsin deficiency has not been thoroughly investigated 
previously. This too should be the focus of future endeavours. The high level of SERPINA1 expression 
within cartilage suggests mutations within the SERPINA1 gene (rendering a weaker/non-functional AAT) 
may have significant consequences for the integrity of the tissue during periods of inflammation.  
There are limitations to this study. Although our observations regarding cleavages (and cleavage sites) are 
novel and important, we must be candid about extrapolating biochemical observations to the OA joint. To 
determine pathophysiological importance of neutrophil elastase on MMP-13 activation in OA, future 
studies would need to: 1) determine of the level of active neutrophil elastase in the OA joint; 2) assess how 
this compares to the level of proMMP-13 in the cartilage; 3) establish the degree of AAT inactivation and 
therefore the viable inhibitor pool in the OA joint; 4) How these change with stage and severity of OA (and 
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preclinical models of OA will prove important in this regard. Recently, Kaneva and colleagues 
demonstrated that AAT protected cartilage in two animal models of inflammatory arthritis, including one 
induced by neutrophil elastase [72]. Our study both supports and compliments these observations and 
provides novel insights into the proteolytic interplay between AAT, neutrophil elastase and MMP-13, with 
potential consequences for the destruction of OA cartilage. AAT can have a role beyond proteinase 
inhibition [61], however, and the authors conclude that AAT was not only chondroprotective but also anti-
inflammatory and has a significant effect on pain [72]. This study and our own highlight the need to also 
investigate the effects of AAT administration using in vivo models of OA, with direct quantification of 
cartilage degradation, pain and inflammation.
The importance of synovial inflammation in OA progression is contested, and we agree with the central 
role of dysregulated chondrocyte biology in OA cartilage destruction. However, we and others have 
demonstrated a variable degree of synovitis in OA patients (reviewed in [73]), and in these instances, it is 
credible that neutrophil elastase - given its activation potency and ability to generate a fully active MMP-13 
- will contribute to OA cartilage collagen destruction through direct activation of latent MMP-13. The 
search for in vivo activators of MMP-13 is important, particularly as this represents a key control point for 
cartilage destruction and may represent a novel approach for therapy. The rapid, full activation of MMP-13 
by neutrophil elastase may have significance in a subset of OA patients where an inflamed synovium 
contributes to the progression and exacerbation of the disease process.
Materials and Methods
Reagents
Unless stated otherwise all reagents were of the highest purity and purchased from Sigma Aldrich 
(Gillingham, UK). Human neutrophil elastase (EC 3.4.21.37) purified from human sputum was purchased 
from Elastin Products (SE663; MO, USA). AAT protein was purified as described previously [74]. Human 
recombinant proMMP-1 (E.C. 3.4.24.7) and proMMP-13 (E.C. 3.4.24.B4) were expressed using an insect 
cell expression system (and purified) as previously described [11, 37]. Recombinant human proMMP-8 
(E.C. 3.4.24.34) was purchased from R&D Systems (908-MP-010; Abingdon, UK). Recombinant human 
active MMP-3 EC (3.4.24.17) was expressed and purified as previously described [75]. Recombinant 
human matriptase (E.C. 3.4.21.109) and hepsin (E.C. 3.4.21.106) were expressed and purified as previously 
described [37]. Recombinant human full-length tissue-inhibitor of metalloproteinase (TIMP)-1 was a kind 
gift from Celltech Pharmaceuticals, Slough, UK. Elastase fluorogenic substrate (CAS 72252-90-5), MMP 
fluorogenic substrate (FS-6; SCP0193) and GM6001 were purchased from Merck Millipore (Watford, UK). 
Neutrophil elastase (ab68672) and MMP-13 (Ab75606) antibodies were from Abcam (Cambridge, UK). 
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healthcare (GE Healthcare, Chalfont St Giles, UK). Cytochalasin B and f-Met-Leu-Phe (fMLP), were from 
Sigma Aldrich. Granulocyte-macrophage colony-stimulating factor (GM-CSF) was from Roche Applied 
Biosciences (Burgess Hill, UK). 
Human tissue and cartilage explant culture
All tissue was taken with informed consent from patients undergoing total joint replacement at the Freeman 
Hospital in Newcastle upon Tyne. All OA tissues (cartilage, synovium and synovial fluid) were handled 
according to Newcastle University guidelines with ethical approval from NHS Health Authority NRES 
Committee North East – Newcastle and North Tyneside (REC14/NE/1212). Neutrophils were isolated from 
consenting healthy donors at the University of Liverpool, approved by the University of Liverpool 
Research Ethics Subcommittee for physical interventions (Ref: 1672). For cartilage explant cultures, 
macroscopically intact human OA cartilage was cut from the tibial plateau (approximately 2 mm3 pieces) 
and cultured overnight in 24 well plates (3 chips per well) in serum-free Dulbecco’s Modified Eagle’s 
Medium (DMEM) (supplemented with glutamine (2 mM), penicillin/streptomycin (200IU/ml and 200 
g/ml, respectively) and nystatin (40 IU/ml)). The following day, explants were stimulated with neutrophil 
elastase for the time period and concentrations indicated. At the end of the experiment, medium was 
harvested and remaining cartilage digested with papain as previously described [51]. For both medium and 
digested cartilage, hydroxyproline (OHP) assays were performed to assess percentage collagen destruction, 
whilst proteoglycan destruction was assessed by measuring glycosaminoglycan (GAG) levels using 
dimethyl methylene blue (see [51] and references therein). 
In vitro incubations, SDS-PAGE and N-terminal sequencing
For in vitro incubation experiments, neutrophil elastase (20 nM) was incubated with proMMP-13 (100 nM) 
in ‘reaction buffer’ (100 mM Tris pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.01% (w/v) Brij35) for the 
indicated time points at 37°C, in a final volume of 20 µl. 4-Aminophenylmercuric acetate (APMA) was 
used a positive control (0.67 mM). For inactivation experiments, AAT (50 nM) was incubated with MMP-
13 (10 nM), APMA, or both for 16 hours at 37°C. The incubation products (10 µl) were subsequently 
incubated with neutrophil elastase to determine inhibitory capacity (see below for assay details). For 
protein gels, digestion products (10 µl for AAT inactivation and 20 µl for proMMP-13 activation 
experiments) were mixed with 5x sample buffer (625 mM Tris HCl pH 6.8, 10% (w/v) SDS, 40% (v/v) 
glycerol, 0.5% (w/v) bromophenol blue, 3% (v/v) ß-mercaptoethanol) and separated by 10% SDS-PAGE as 
described previously [37]. Gels were subsequently stained using a PlusONE silver staining kit according to 
the manufacturer’s instructions (GE healthcare). For low molecular mass products of AAT digests, peptides 
were detected by separating reaction products by Tris-Tricine SDS-PAGE as described previously [76]. For 
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stained with Coomassie brilliant blue for 2 minutes. Bands were excised with a clean scalpel blade and sent 
for N-terminal sequencing (Alphalyse, Denmark).  
Enzyme activity assays
To test MMP activation, proMMP-1, -8 and -13 were incubated with elastase as described above, for 4 
hours. As a negative control, an excess of AAT (1.14 mg/ml) was included, which demonstrated the 
requirement for elastase activity. Incubation products (5 µl) were added to white-walled plates and diluted 
to 80 µl in MMP assay buffer (reaction buffer with 0.1% (v/v) polyethylene glycol 6000). MMP 
fluorogenic substrate (FS-6) was added to start the reaction at a final concentration of 10 µM, to a total well 
volume of 100 µl. Reaction velocity was calculated by linear regression of initial rates of progress curves. 
For mole-per-mole comparison experiments: neutrophil elastase was titrated with freshly resuspended AAT 
protein (Merck Millipore; 178251); MMP-3 was titrated with full-length TIMP-1; while matriptase and 
hepsin were titrated with 4-methylumbelliferyl 4-guanidinobenzoate (MUGB). ProMMP-13 (100 nM) was 
incubated with 20 nM of each enzyme for 4 hours in the reaction buffer described above prior to 
conducting the MMP activity assay. To measure MMP activity in human OA cartilage conditioned media, 
50 µl of medium was used with FS-6 substrate as described above. To test AAT inhibitory capacity 
following MMP-13 incubation, elastase activity assays were performed in a similar manner using elastase 
activity buffer (100 mM Tris pH 7.6, 150 mM NaCl, 0.01% (w/v) Brij 35) and an elastase fluorogenic 
substrate (MeOSuc-AAPV-AMC) at a final concentration of 20 µM. Neutrophil elastase was used at a final 
concentration of 5 nM. 
Neutrophil isolation, degranulation and MMP-13 activation
Neutrophils (purity typically >97%, assessed by cytospin) were isolated from heparinised whole blood 
using HetaSep and Ficoll-Paque as previously described [77] and resuspended at 5x106 cells/ml in 1 ml of 
RPMI 1640 media supplemented with HEPES (25 mM) and L-glutamine (2 mM).  Neutrophils were 
incubated with GM-CSF (5 ng/ml) for 30 min followed by cytochalasin B (6 g/ml) and f-Met-Leu-Phe 
(fMLP, 1 M) for a further 30 min.  Following incubation, cells were pelleted at 1000 x g for 3 min and 
supernatant decanted into clean tubes. Degranulation products (supernatant; 5 l) from either treatment 
were incubated with proMMP-13 (100 nM) for 2 hours at 37C. Controls of the degranulation stimulants 
(Cytochalasin/GM-CSF/fMLP mix in the absence of neutrophils) were also incubated with proMMP-13. 
AAT (50 nM) was included as a negative control. After the incubation, 5 l was added to a white-walled 
96-well plate and an MMP-activity assay was undertaken as described above. Data are presented as mean ± 
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mixed with 5x sample buffer (as above), boiled, and kept at -20C until the products were separated by 
SDS-PAGE and western blotting performed (see below). 
Western Blotting
For western blotting, samples were separated by SDS-PAGE using 10% (w/v) precast acrylamide gels and 
transferred onto Polyvinylidene fluoride (PVDF) using the Transblot Turbo apparatus (BioRad, Watford, 
UK). Blots were blocked in 5% (w/v) non-fat dry milk for 1 hour, washed in tris-buffered saline-Tween20 
(TBS-T), prior to overnight incubation at 4C with an MMP-13 antibody (sc-30073, Santa Cruz, USA), 
diluted 1:2000 in 5% (w/v) bovine serum album (BSA). Blots were then further washed in TBS-T prior to 
incubation with an anti-rabbit secondary (GE healthcare, Bucks, UK) at 1:2000 dilution in milk for 1 hour. 
Blots were washed again in TBS-T and detected using enhanced chemiluminescent substrate (ECL; 
ThermoFisher, Loughborough, UK). 
Enzyme-Linked Immunosorbent assay (ELISA)
Levels of MMP-13 and neutrophil elastase in human OA knee synovial fluids (8 samples; 6 females/2 
males; age 69.510.4) were determined by ELISA according to the manufacturer’s instructions (R&D 
Systems). Briefly, Maxisorp plates (ThermoFisher) were incubated with coating antibody overnight at 4ºC. 
Plates were washed in phosphate buffered saline (PBS) with Tween (0.1% v/v) and blocked in 300 µl of 
1% (w/v) BSA in PBS for 1 hour. Plates were washed and standards and samples (100 µl; neat or diluted in 
PBS) were loaded onto the plates and incubated overnight. Plates were washed and detection antibody 
diluted in PBS with 0.1% (w/v) BSA added to the wells. Plates were washed and streptavidin-horseradish 
peroxidase (HRP) diluted in PBS with 0.1% (w/v) BSA. Colour development was initiated by the addition 
of o-phenylenediamine dihydrochloride substrate solution, the reaction stopped with 3M HCl and the 
absorbance read at 490 nm. 
Histology and Immunohistochemistry
Human synovial tissues (17 patients, 14 Female/3 male, mean age = 65 years  9.2) were fixed in 10% 
formalin, embedded in paraffin and sections were taken at 4 µm intervals. Haematoxylin and eosin (H&E) 
staining was performed as previously described [11] and synovitis scored according to a previously 
described system [37, 40]. Immunohistochemistry was performed essentially as previously described [37], 
except antigen retrieval was performed using a mini autoclave (Aptum 2100 retriever; Aptum, 
Southampton, UK) for 30 minutes. Primary antibodies for neutrophil elastase and MMP-13 were used at 
1:100 dilution (both 10 µg/ml) for 1 hour, and staining conducted using Vectastain Elite ABC HRP Kit 
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OA cartilage samples from patients undergoing total hip replacement (mean age 61.3 ± 7.5, 3 x Female) or 
from hip replacement following fracture (NOF; mean age 74 ± 8.4, 1 x male, 1 x female) were fixed, 
embedded and sectioned as described above. Serial sections were stained with safranin-O or underwent 
IHC staining using an antibody against AAT protein (16382-1-AP; Proteintech, Manchester, UK) at 1:150 
dilution (3.2 µg/ml) for 2 hours, followed by signal detection using Vectastain Elite ABC HRP Kit. In all 
cases, sections treated in the same manner in the absence of a primary antibody, or with an isotype control 
antibody (R&D systems; AB-105-C) at the same concentration as the corresponding primary antibody, 
served as negative controls. Images were taken using a Leica Biosystems DM4000B light microscope.
Bioinformatic analyses and protein visualisation
Transcripts per million (TPM) values in control cartilage (NOF) samples were generated using Salmon as 
described [39] whilst Human Protein Atlas TPMs were retrieved from the Human Protein Atlas ([78]; 
www.proteinatlas.org). R software was used to generate figures from RNA sequencing data in Figures 6A 
and 6B. For structural images, AAT was visualised using PyMol software (version PyMOL v1.7.6.6 
Enhanced for Mac OS X) using the structure of the intact protein (Protein Data Bank (PDB) ID 1QLP; 
[79]).  
Statistics
Statistical analyses where multiple comparisons are required were performed using a one-way ANOVA 
with a Tukey’s post-hoc test. In all cases, * p<0.05, ** p<0.01, *** p<0.001 and data are presented as mean 
 standard deviation (SD). RNAseq statistical analysis was performed using DESeq2 where p-values were 
adjusted using the Benjamini-Hochberg method which controls for the false discovery rate (<0.05).
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Figure Legends
Figure 1. Neutrophil elastase-induced collagen release is MMP-dependent
Neutrophil elastase (NE) was added to human OA cartilage for a period of 7 days in the presence or 
absence of the MMP inhibitor GM6001 (10 M), DMSO vehicle control (0.02% v/v) or AAT protein (100 
μg/ml), after which the medium was removed and remaining cartilage digested with papain as described 
previously [51]. A) Collagen breakdown was determined by hydroxyproline assay. B) MMP activity was 
determined in conditioned medium using an MMP-specific quenched fluorescent peptide. C) Proteoglycan 
release was determined by measurement of sulphated glycosaminoglycan (GAG) using a DMMB assay. D) 
GM6001 or its vehicle DMSO had no effect on neutrophil elastase activity, as determined in vitro using the 
elastase specific quenched-fluorescent peptide, MeOSuc-AAPV-AMC. Matrix breakdown is expressed as a 
percentage of the total, which is determined by level of GAG or hydroxyproline in the conditioned medium 









This article is protected by copyright. All rights reserved
least three independent experiments, while inclusion of the metalloproteinase inhibitor, GM6001 was 
conducted twice. Data are presented as mean ± SD (n=4) with statistical analyses performed using a One-
way ANOVA with Tukey’s post-hoc test where *= p<0.05, **=p<0.01 and ***= p<0.001; ns = not 
significant.
Figure 2. Neutrophil elastase potently activates MMP-13 in vitro
Neutrophil elastase (NE) was incubated with A) proMMP-1, B) proMMP-8 and C) proMMP-13 in a 1:5 
enzyme to substrate ratio at 37°C for 4 hours. Activation with the chemical activator APMA (0.67 mM) 
was used as a positive control, whilst neutrophil elastase in combination with an excess of AAT (1.14 
mg/ml) served as a negative control, demonstrating the requirement of elastolytic activity. After 4 hours, 
MMP activity was determined using MMP fluorogenic substrate (final MMP concentration was 5 nM). D) 
Mole-per-mole comparisons of neutrophil elastase with MMP-3, matriptase and hepsin for their MMP-13 
activation capability. Reaction velocities were calculated by linear regression of progress curves. Data are 
presented as mean ± SD of 3 independent experiments with statistical analyses performed using a One-way 
ANOVA with Tukey’s post-hoc test where *** = p<0.001 compared to proMMP alone, ### = p<0.001 
compared to proMMP-13+NE, ns = not significant compared to proMMP alone (n=3).
Figure 3. Neutrophil elastase cleavage results in an N-terminus indicative of a fully active MMP-13. 
A) For time course experiments, neutrophil elastase (NE) was incubated with proMMP-13 in a 1:5 enzyme 
substrate ratio in a final volume of 20 µl for the time points indicated. Reactions were stopped by the 
addition of 5x sample buffer and the products separated by SDS-PAGE and stained with silver. B) 
Densitometry of the activation timecourse calculated as percentage of active MMP-13 compared to 
proMMP-13 at each timepoint. Data presented as mean ± SD from three independent experiments. C) Dose 
response experiments were conducted over 4 hours with 1:1000, 1:100, 1:50 ,1:20, 1:10, 1:5 and 1:1 
neutrophil elatase:MMP-13 ratios, followed by silver stain (C) and MMP activity assay (D). E) The 
inclusion of the broad-spectrum metalloproteinase inhibitor GM6001 was used to determine direct and 
indirect cleavage. F) To identify cleavage sites, similar experiments were performed, with products 
separated by SDS-PAGE and blotted onto PVDF. Blots were briefly stained with Coomassie and both the 
full cleavage product (full) and the intermediate species (int) generated in the presence of GM6001 were 
subject to analysis by N-terminal sequencing. Sequencing gave 5 unambiguous amino acid reads at each 
site which correspond to the cleavage sites as depicted. Solid arrow corresponds to the final N-terminus in 
the absence of metalloproteinase inhibition, whereas the dashed arrow corresponds to cleavage by 
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Figure 4. MMP-13 is activated by neutrophil degranulation products
Purified neutrophils were primed with GM-CSF for 30 minutes, stimulated with cytochalasin B + fMLP for 
a further 30 minutes, and supernatants harvested. A) Neutrophil elastase was detected in supernatants from 
degranulated neutrophils and elatase activity could be detected in these samples using an elastase-specific 
quenched fluorescent peptide, MeOSuc-AAPV-AMC (B; timepoints shown as mean ± SD). Degranulation 
products were incubated with proMMP-13 for 2 hours for donors 1 and 3 (blue and red, respectively) and 
30 minutes for donor 3 (green), due to high proteolytic activity in degranulated neutrophils this donor. 
MMP activity was measured with an MMP-specific quenched fluorescent substrate (FS-6; C, upper panel) 
and neutrophil elastase activity was also determined using an MeOSuc-AAPV-AMC (C, lower panel). 
MMP-13 activation was further demonstrated using western blotting (D, upper panel), and a neutrophil 
elastase western blot was performed to act as a loading control (D, lower panel). Treatment with 
stimulation cocktail alone did not cause MMP-13 to be activated, and inclusion of AAT blocked processing 
of proMMP-13. Activity shown from 3 independent donors (bars represent mean ± SD) while the western 
blots are representative of all 3 donors. Statistical analyses of MMP activity were performed using a One-
way ANOVA with Tukey’s post-hoc test where ***= p<0.001 compared to proMMP-13 alone, 
###=p<0.001  compared to proMMP-13 with degranulation products (n=3).
Figure 5. Neutrophil elastase is detectable in OA synovial tissue and synovial fluid
A) Human synovial tissue from OA patients (N=17, 14 Female/3 male, mean age = 65 years ± 9.2) was 
embedded and sectioned. Sections of different depths were stained with haematoxylin and eosin and the 
level of synovitis scored according to a previously described scoring system [40] where samples were 
categorised as having no synovitis (0-1), slight synovitis (2-3), moderate synovitis (4-6) or strong synovitis 
(7-9). Immunohistochemistry was performed using antibodies to neutrophil elastase and MMP-13. Sections 
where no primary antibody was included, as well as an isotype control antibody at the same concentration 
as primary antibody, served as negative controls. Neutrophil elastase was absent from samples categorised 
as having ‘no synovitis’ (synovitis score <1; 0/3), but present in the majority of samples with a synovitis 
score >1 (11/14). MMP-13 was detectable in all synovial samples regardless of synovitis grade. Synovial 
fibroblasts are indicated with red arrows, invading leukocytes with green arrows and blood vessels with 
orange arrows. Neutrophil elastase mainly stained positive in leukocytes and blood vessels. MMP-13 was 
detectable in fibroblasts and invading leukocytes. Images taken at 40x magnification and scale bars 
represent 50 µm. In synovial fluid samples from different patents, levels of neutrophil elastase (B) and 
MMP-13 (C) were determined by sandwich ELISA. Data points are from 8 individual donors (N=8, 6 
females/2 males; age 69.5±10.4) with bars representing mean ± SD. D) MMP-13 levels did not correlate 
with neutrophil elastase levels, and neither proteinase significantly correlated with erthyrocyte 
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Figure 6. SERPINA1 gene expression is abundant in human cartilage and the alpha-1 antitrypsin (AAT) 
protein localised predominantly in the superficial layer.
A) The top 50 most abundant genes within a control non-OA cartilage dataset (GSE111358). When ordered 
by transcript per million (TPM), SERPINA1 is the 9th most abundant transcript in hip cartilage. B) 
Comparison of SERPINA1 expression in human tissues using TPM values in control non-OA (neck of 
femur fracture; NOF) hip cartilage samples were generated using Salmon as described [39] and Human 
Protein Atlas TPMs were retrieved from the HPA website [78]. C) SERPINA1 transcript expression is 
significantly reduced in macroscopically intact OA cartilage compared to intact control NOF fracture 
cartilage. Data shown as individual TPM from each donor with bars representing mean ± SD. Adjusted p-
value shown is calculated by DESeq2 analysis using a Benjamini post-hoc test. D) Immunohistochemistry 
of damaged regions from cartilage samples (both OA and NOF controls) shows that AAT staining localises 
to areas of damage and staining intensity increases with level of cartilage destruction. Sections where no 
primary antibody was included, as well as an isotype control antibody at the same concentration as primary 
antibody, served as negative controls. Cartilage proteoglycan loss was determined by safranin-O (Saf-O) 
staining. AAT is localised predominantly to chondrocytes in the superficial and upper middle zone of the 
tissue. Images taken at 20x magnification and scale bars represent 100 µm. 
Figure 7. MMP-13 inactivates alpha-1 antitrypsin (AAT)  
A) Human purified AAT was incubated with proMMP-13 in a 1:5 ratio for 16 hours at 37ºC in a final 
volume of 20 µl. ProMMP-13 was activated by APMA (0.67 mM). Products were separated by SDS-PAGE 
(10 µl) and stained with silver. B) In similar experiments, 5 µl of incubation products was added to activity 
assays, in which neutrophil elastase (NE; 5 nM) was incubated with an elastase specific fluorogenic 
substrate (20 µM). Reaction velocities were calculated from linear progress curves of 3 independent 
experiments, and data plotted as mean ±SD. Statistical analysis calculated by One-Way ANOVA with a 
Tukey’s post-hoc test where *** = p<0.001 (n=3). C) A time course experiment was performed and 
incubation products were separated by both (i) 10% tris-glycine (protein) and (ii) 20% tris-tricine (peptide) 
SDS-PAGE. All gels and activity assays are representative of three independent experiments. D) Cleavage 
sites were identified by N-terminal sequencing of the peptide products. MMP-13 cleaves upstream of the 
neutrophil elastase (NE) cleavage site in two positions, disarming the inhibitor, as depicted in both protein 
sequence (upper panel) and structural view (lower panel). SERPINA1 was visualised using PyMol software 
(PDB ID: 1QLP). The flexible reactive centre loop (bait region) is shown in green, and P1 residues at 
cleavage sites are shown for both MMP-13 (blue - Phe376 and Pro381) and neutrophil elastase (NE; red - 
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between neutrophil elastase, MMP-13 and AAT in cartilage. Neutrophil elastase fully activates MMP-13, 
which can result in collagen breakdown. Rapid and specific inactivation of AAT by MMP-13 (along with 
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